MILabs B.V. is pleased to announce that the Institute of Experimental Molecular Imaging (ExMI) at the RWTH Aachen University has chosen the MILabs high-resolution CT to further enhance its world-leading molecular imaging research.
Together with the new MILabs optical tomography system, this unrivaled hybrid OI/CT system enables 3D/4D quantitative imaging in deep-tissues guided by high-contrast X-ray CT images, obtained at extremely low radiation doses.
The low-dose CT and tomographic optical imaging capabilities of the system support our work in the field of nanomedicines and theranostics, and their application to diagnose and treat oncological and cardiovascular diseases. We are focused on research of new devices, contrast agents, therapeutics and postprocessing tools.
Using high-contrast CT to guide 3D optical imaging is critical for these applications and we are glad thatMILabs has embraced and adopted our Imalytics CT-segmentation and fluorescence reconstruction approaches developed by Dr. Felix Gremse, one of the group leaders within our institute”
Professor Fabian Kiessling, Director of the ExMI Institute
We are pleased with the application tests performed by ExMI to validate our unique 3D/4D Optical/CT imaging capabilities. Optical/CT further extends the application range of our award-winning VECTor molecular imaging platform from bench-to-clinic.
This scalable integrated platform now includes PET, SPECT, quantitative 3D autoradiography, radiotherapy imaging, luminescence, fluorescence and X-ray CT."
Professor Dr. Frederik Beekman, MILabs Founder and CEO
Research suggests no need for yellow fever vaccine booster after initial dose